As monoclonal antibody (mAb) development continues to evolve, new challenges are arising in the purification process, especially during the polishing stage. Innovations in flow-through technology – ...

Monoclonal antibody (mAb) development continues to evolve – with increasingly complex formats demanding more sophisticated purification methods, especially during the polishing stage. Challenges such ...

Vendors Bank on the Prospect of Successful End-to-End Continuous Manufacturing for Biologics Continuous processing has been a mainstay in process industries for decades, but is conspicuously rare in ...

Next-generation manufacturing of monoclonal antibodies (mAbs) will rely on continuous processes featuring single-use adsorbents, small-footprint production, and minimal aqueous buffer volumes, ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Although biopharmaceutical manufacturing covers an extensive range, it is essential that each iteration of a unit operation is in compliance with an unyielding set of operational parameters and ...